IgAN is an autoimmune kidney disease that occurs when clumps of immunoglobulin A and antibodies are deposited in the kidneys, causing inflammation and kidney damage which leads to blood and protein leaking into the urine.2 

The Health Canada authorization is based on a prespecified interim analysis results at 36 weeks of the Phase III ALIGN study, a randomized, double-blind, placebo-controlled study in adults ≥ 18 years with biopsy-proven primary IgAN, estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m² and total urine protein ≥ 1 g/day who were on a stable dose of maximally tolerated renin-angiotensin system inhibitor therapy.¹

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.